Dermal fibroblast senescence is measurable in skin biopsies from all aging trials — both D+Q and fisetin studies measure skin biomarkers (p16, p21) as accessible surrogate endpoints for systemic senescent cell burden. Skin benefits from senolytics are both a primary biological effect (dermal rejuvenation) and a convenient measurable outcome for clinical studies.

Will senolytics visibly improve skin appearance?

Many longevity practitioners and users report improved skin texture, reduced redness, and improved wound healing with regular senolytic protocols. Controlled cosmetic outcomes trials have not been completed.

How do UV protection and senolytics interact?

Sunscreen reduces UV-induced senescence induction — reducing the rate of new senescent cells. Senolytics clear already-senescent cells. Both are needed: prevention (sunscreen) + clearance (senolytics).